Incheon City envisions Biotech Mecca by developing Songdo Global Biotech Cluster

The Incheon Metropolitan City government has announced an ambitious plan for the development of the Songdo Global Biotech Cluster in the Incheon Free Economic Zone. In order to attract the world’s leading biotechnology companies and research institutions, the city will develop the industrial complex by adding the 11th Songdo industrial block.

They will develop the Songdo region as a world leading biotech center on a global scale by connecting the industrial complex with the planned nearby Songdo Severance Hospital and a science park.

Stay informed on the latest biotech news with Born2Invest. Our companion app includes updates of finance headlines from business and investing in cannabis, Africa, fin-tech, and more.

To attract leading biotechnology companies and research institutions, the city will expand the industrial complex with the 11th Songdo Industrial Block covering 990,000 square meters and the 4th, 5th and 7th Songdo Industrial Block covering 910,000 square meters. They will develop the Songdo region as a global biotech center by connecting the industrial complex with the planned nearby Songdo Severance Hospital and Science Park.

The city administration is concentrating on expanding the investor base. In 2018, it conducted investor relations activities in Switzerland to focus on technology and business developments in the country’s biotech industry. Representatives of the city visited Novartis, a global biopharmaceutical company, to discuss the possibility of investing in the biotech cluster.

Gudel Lineartec Co Ltd, a Swiss-based industrial robot manufacturer, opened its production facilities in the Songdo region in 2005. Several Swiss-based companies, including Roche, Novartis, and Bioengineering, established partnerships with biotech companies in Songdo. Biotech companies in the city also took part in the Europe Biotech Forum, the largest industry event in Europe.

The city administration is currently carrying out contract research with the aim of analyzing important tasks for the expansion of the Songdo Biotech Cluster and developing a feasible overall concept by the end of the year. The study includes opportunities to identify demand from new investors, attract large-scale facilities and promote Korean biotech companies in the cluster.

“The Songdo complex has achieved remarkable growth in the global biopharmaceutical market. The incentive for more investment by advanced global pharmaceutical companies and the building of partnerships with them is essential to building a world-class biotech cluster,” said Park Nam-Choon, Mayor of Incheon City.

“We are committed to contributing to the growth of the Korean bio-pharmaceutical industry. While complementing susceptible industries in the development of the Songdo Global Biotech Cluster. And inducement of more investment by creating a more favorable environment for global pharmaceutical companies and maximizing Korean industry’s research and development capabilities.”

 __

(Featured image by Mathew Schwartz via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in boerse.de, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.